Sage Journals: Discover world-class research

Abstract

BACKGROUND:

Non-small cell lung cancer (NSCLC) is the main type of lung cancer. While miR-186 is significantly reduced in lung cancer tissues and cells, its role in NSCLC has not been completely elucidated.

MATERIAL AND METHODS:

We used qRT-PCR and western blot methods to investigate the levels of miR-186 and YY1 in 21 pairs of NSCLC tissues. Dual luciferase reporter gene assays were performed to detect whether miR-186 directly targets YY1. Next, the roles of miR-186 and its target gene (YY1) in determining the proliferation, apoptosis and migration capabilities of selected cell lines (A549 and HCC827) were investigated by using miR-186 mimics or YY1 siRNA.

RESULTS:

Our results showed that miR-186 was downregulated and YYI was upregulated in NSCLC tissue, and miR-186 expression was negatively associated with YY1. Similarly, miR-186 was also downregulated and YY1 expression also was upregulated in both A549 and HCC827 cells; furthermore, miR-186 was found to directly target YY1. Cell proliferation, invasion, and migration, as well as apoptosis induction were more strongly inhibited by YY1 siRNA than by miR-186.

CONCLUSION:

Our results suggest that miR-186 and its target gene (YY1) could possibly serve as new prognostic biomarkers and therapeutic targets for treating NSCLC in humans.

Keywords

miR-186 YY1 cell proliferation apoptosis migration and invasion non-small cell lung cancer

1. Background

Lung cancer is one of the most common malignant tumors in China. Data released by the National Cancer Center of China in 2015 showed that lung cancer ranked first in both incidence and mortality among all malignant tumors in China during 2011 [1]. Additionally, according to the American Cancer Society, the latest statistics for a population of Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs) estimate 3460 and 3030 new cases of lung cancer among males and females, respectively. This means that in 2016, lung cancer will account for 14% of all new cancers in males, 9% of all new cancers in females, and rank second and third in cancer incidence among males and females, respectively. The numbers of deaths among male and female lung cancer patients are expected to be 2290 and 1780, respectively, and will account for 27% of all cancer-related deaths among males and 21% of all cancer-related deaths among females, making lung cancer the leading cause of cancer-related death [2]. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancers, and includes subgroups of squamous cell carcinoma, lung adenocarcinoma, and large cell carcinoma [3, 4]. Most cases of NSCLC have already metastasized when they are diagnosed [5, 6, 7], making treatment of advanced stage patients the fastest growing group of lung cancer patients in recent years. Surgery, radiotherapy, and chemotherapy are the traditional methods used to treat lung cancer. While surgery is the most common treatment for NSCLC patients, combined radiotherapy plus chemotherapy is the primary treatment for patients with advanced NSCLC. However, the clinical outcomes of these treatment methods are often not ideal, and the overall prognosis for NSCLC patients remains poor, as the 5-year survival rate is only 5%–15.8% [8, 9, 10]. In recent years, significant progress has been made in studying the molecular genetics of lung cancer. As a result molecular targeted therapy is playing an increasingly important role in treating individual patients with advanced lung cancer.

MicroRNAs (miRNAs) are naturally occurring, short, non-coding RNAs that negatively regulate gene expression [11]. In mammals, mature miRNAs consist of 21–24 nucleotides, integrate into RNA-inducing silencing complexes, and pair with the 3 ${}^{\prime}$ untranslated regions (3 ${}^{\prime}$ UTRs) of their target mRNAs to suppress the translation or induce degradation of the target mRNAs [12]. MiR-186 is one of the miRNAs thought to be involved in various diseases, such as cardiovascular disease [13] and various cancers, including gastric cancer [14], prostate cancer [15], and NSCLC [16, 17]. MiR-186 acts as a tumor suppressor by inhibiting cyclin D1, cyclin-dependent kinase (CDK)2, and CDK6 expression in NSCLC tissue. In colorectal cancer, miR-186 induces cell apoptosis by targeting CKII $\alpha$ . However, the target molecular of miR-186 in NSCLC cells has remained unclear.

Yin Yang 1 (YY1) is a relatively conserved transcription factor that plays important roles in embryonic development, differentiation, and cell proliferation. In addition, it plays a direct regulatory role in the metastasis and invasion of solid tumors [18]. However, little is known about how the YY1 gene is regulated.

MiR-186 expression is significantly downregulated in colorectal cancer cell lines SW620 and LoVo, and also in colon cancer tissue when compared with its expression in adjacent tissues. Transfection with the recombinant lentiviral vector PLVTHM-miR186 significantly inhibits cell proliferation, migration, and invasion, and suppresses YY1 protein expression in SW620 cells [20]. The goal of the current study was to determine whether miR-186 inhibits cell proliferation, migration, and invasion by directly targeting YY1 in NSCLC cells.

2. Material and methods

2.1 Specimens

Twenty-one pairs of NSCLC tissue specimens and adjacent normal tissue specimens were obtained from 21 different patients who had visited the Shenzhen People’s Hospital. All patients who participated in this study provided their written informed consent. The investigation and experimental protocol were approved by the Ethics Committee of Shenzhen People’s Hospital.

2.2 Cell culture

Human lung cancer cell lines A549, 95-D, HCC827, and NCI-H1650, and lung epithelial cells (HPAEpiC) were purchased from ATCC (Manassas, VA, USA). All cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 $\mu$ g/mL streptomycin, and 100 U/mL penicillin in a humidified atmosphere of 5% CO ${}_{2}$ at 37 ${}^{\circ}$ C.

2.3 Transfection

MiR-186 mimics, small-interfering RNAs targeting YY1 (si-YY1), and their respective negative controls were obtained from Gene Pharma (Shanghai GenePharma Co. Ltd, Shanghai, China). Cells were seeded into six-well plates (2 $\times$ 10 ${}^{5}$ cells/well) and cultured for 24 h; after which, they were transfected with miRNA mimics (50 nM), miR-NC (50 nM), YY1 siRNA or NC siRNA by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions. At 48 h post-transfection, the cells were harvested and tested for miR-186 and YY1 expression, prior to their use in subsequent experiments.

Table 1
Primer sequences used for miRNA and mRNA expression analysis

Name	Primer sequence (5’-3’)
miR-186-RT	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTTTGGGCT
U6-RT	CGCTTCACGAATTTGCGTGTCAT
U6-F	CTCGCTTCGGCAGCACA
U6-R	AACGCTTCACGAATTTGCGT
miR-186-F	ACACTCCAGCTGGGCAGCAGCACACT
Universal-R	CTCAACTGGTGTCGTGGA
YY1-F	CTGGAGGAATACCTGGCAT
YY1-R	TTGGTGTCGTTTTAGTTTTGAA
GAPDH-F	TGTTCGTCATGGGTGTGAA
GAPDH-R	ATGGCATGGACTGTGGTCAT

$F$ forward primer, $R$ reverse primer, RT reverse transcription primer.

2.4 Dual luciferase reporter gene assay

The binding sites for miR-186 within YY1 mRNA were predicted, and the wild-type YY1 3’-UTR (wt 3’-UTR) fragment containing the predicted miR-186 binding sites was amplified by PCR. Mutant YY1 3’-UTR (MUT 3’-UTR) was obtained by mutating the conserved binding sites for miR-186. Fragments which including the wt 3’-UTR or MUT 3’-UTR regions of YY1 were cloned into a psiCHECK-2 vector (Promega, Madison, WI, USA) that contained both Renilla and firefly luciferase reporter genes. The psiCHECK-2 vectors with the wt 3’-UTR or MUT YYI 3’-UTR regions were transfected into HEK23 cells that had been previously transfected with miR-186 mimics or negative control mimics, respectively, by using Lipofectamine 2000 (Invitrogen, USA). After 24 hours, the firefly and Renilla luciferase activities in the cells were determined with a dual-luciferase reporter assay system (Promega) in accordance with the manufacturer’s instructions.

2.5 qRT-PCR

After treatment, total RNA was extracted using TRIZOL (Invitrogen). The stem-loop primers used for PCR amplification were synthesized by RiboBio (Beijing, China). The relative level of miR-186 expression was normalized against the level of U6 expression. Real-Time PCR reactions were conducted using TaKaRa SYBR Premix Ex Taq II (TaKaRa, Shiga, Japan) on an Applied Biosystems 7500 Real-Time PCR System (ABI, Foster City, CA, USA). The level of YY1 gene expression was normalized to the level of GAPDH expression within each sample using the $\Delta\Delta$ CT method. Gene expression is shown as a value relative to expression of the control. The results were calculated from data obtained in three independent experiments. The primers used in the study are listed in Table 1.

2.6 Western blot studies

Tissue specimens or cells were homogenized, and their total proteins were extracted with ice-cold SDS lysis buffer (Beyotime, Haimen, China). The protein concentration of each sample was measuring using a Bio-Rad protein assay. Next, 30 $\mu$ g–50 $\mu$ g aliquots of total protein were loaded onto a 8% $\sim$ 12% polyacrylamide gel and separated by performing electrophoresis at 80 V for 30 min, and then at 120 V for 1.5 h. The separated protein bands were then transferred onto a polyvinylidene difluoride (PVDF; Roche, Basel, Switzerland) membrane by electrophoresis at 250 V for 1 h. Following transfer, the membrane was blocked with 5% non-fat dry milk for 1 h, and then incubated with anti-YY1 (1:1000, Abcam, Cambridge, UK) or anti-GAPDH (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight. The next morning, the membrane was repeatedly washed, and then incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature; after which, immunoblots were detected by use of ECL (Beyotime, China).

2.7 CCK-8 assay

Cell proliferation was determined by using a Cell Counting Kit-8 (CCK-8) (Beyotime, China). In brief, cells were cultured to a density of 2 $\times$ 10 ${}^{4}$ cells per well, and then seeded into 96-well plates; after which, they were cultured for an additional 24 h, 48 h or 72 h. Next, 10 $\mu$ L of Cell Counting Kit-8 solution (KeyGen Biotech, Nanjing, China) was added to each well. After a 4 h incubation, the plates were analyzed at 450 nm with a microplate reader Thermo Plate (Rayto Life and Analytical Science C. Ltd, Germany). All values are reported as the mean $\pm$ SD of three values obtained in least three independent experiments.

Figure 1.

Differential expression of miR-186 and YY1 in specimens of NSCLC tissue and adjacent normal tissue. (A) Relative expression of miR-186 in NSCLC tissue and adjacent normal tissue, ${}^{**}p<$ 0.01 ( $n=$ 21). (B) Relative expression of YY1 in NSCLC tissue and adjacent normal tissue, ${}^{*}p<$ 0.05 ( $n=$ 21). (C) Western blot detection of YY1 protein expression in NSCLC tissue and adjacent normal tissue. (D) Analysis of the relationship between miR-186 and YY1 in tumor tissue.

2.8 Cell apoptosis

Cell apoptosis was assessed by using an Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA). Annexin V-FITC (5 $\mu$ L) and propidium iodide (5 $\mu$ L) were successively added to 100 $\mu$ L of cells that were suspended at a concentration of 1 $\times$ 10 ${}^{6}$ cells/mL. After incubation in darkness for 15 min, Annexin V binding buffer was added and apoptosis was analyzed by flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA).

2.9 Migration and invasion assay

Cell migration and invasion assays were performed by using a Transwell chamber (Corning Inc., Corning, NY, USA). The Transwell chamber was precoated with 30 $\mu$ L of Matrigel when detecting cell invasion, but was used without the Matrigel coating when detecting cell migration. Cells were seeded into a 24-well plate and cultured at 37 ${}^{\circ}$ C in culture medium containing 2% serum, while 600 $\mu$ L of 10% FBS – culture medium was added to the lower chamber. After 48 h, the cells were fixed with 100% methanol for 30 min. After removing the non-migrated cells with cotton swabs, the migrating cells were stained with crystal violet for 20 min. Cell images were obtained under a phase-contrast microscope (Olympus, Tokyo, Japan).

2.10 Statistical analysis

All data were analyzed using SPSS Statistics for Windows, and results are expressed as the mean value $\pm$ SD obtained from at least three independent experiments. Statistical analysis was performed by one-way analysis of variance (ANOVA), followed by the SNK multiple comparison post hoc test. P-values $<$ 0.05 were considered statistically significant.

3. Results

3.1 Expression of miR-186 and YY1 in NSCLC tissue

The levels of miR-186 and YY1 expression were examined in 21 pairs of NSCLC tissue and adjacent normal tissues by qRT-PCR (Fig. 1A and B). Our results showed that the levels miR-186 expression in the tumor tissues were significantly lower than those in the normal tissues ( $p<$ 0.01). YY1 mRNA was more highly expressed in tumor tissues when compared with normal tissues ( $p<$ 0.05). Furthermore, the levels of YY1 protein in tumor tissues were also higher than those in normal tissues (Fig. 1C). We then evaluated the relationship between YY1 and miR-186 in tumor tissue (Fig. 1D), and found that miR-186 expression was negatively associated with YY1 expression ( $p=$ 0.0012). Thus, miR-186 was downregulated in NSCLC tissues, while YY1 was upregulated. MiR-186 expression was negatively associated with YY1 expression.

3.2 MiR-186 directly targeted YY1

To investigate whether YY1 was a target of miR-186, the levels of miR-186 and YY1 expression in several human lung cancer cell lines (A549, 95-D, HCC827, and NCI-H1650) and lung epithelial cells (HPAEpiC) were examined to identify the appropriate cells to be studied. The levels of miR-186 in A549 and HCC827 cells were lower than those in HPAEpiC, (Fig. 2A), while YY1 was more highly expressed in A549, 95D, and HCC827 cells than in HPAEpiC (Fig. 2B). Thus, A549 and HCC827 cells were selected for use in the subsequent studies.

Figure 2.

YY1 is the target of miR-186. (A) Expression of miR-186 and (B) YY1 in various human lung cancer cell lines, including A549, 95-D, HCC827, and NCI-H1650, and in lung epithelial cells (HPAEpiC). ${}^{**}p<$ 0.01, ${}^{*}p<$ 0.05 vs. HPAEpiC. After transfection with miR-186 mimics, (C) miR-186 expression was confirmed by qRT-PCR, (D) YY1 mRNA levels were detected by qRT-PCR, and (E) YY1 protein levels were detected by western blot. ${}^{**}p<$ 0.01 vs. NC. (F) The miR-186 seed region in the YY1 3’UTR is shown. (G) The luciferase reporter showed that miR-186 directly targeted YY1. ${}^{**}p<$ 0.01 vs. NC.

Our data showed that transfection with miR-186 mimics upregulated miR-186 expression in the A549 and HCC827 cells (Fig. 2C), and downregulated miR-186 YY1 mRNA expression in both of those cell lines (Fig. 2D). Moreover, western blot studies showed that YY1 protein expression was downregulated by miR-186 (Fig. 2E). Those findings further confirmed that YY1 could be downregulated by miR-186.

TargetScan was used to predict the miR-186 seed region in the YY1 3’UTR (Fig. 2F). The luciferase reporter assay system showed that the relative level of luciferase activity in YY1-3’UTR-WT (wild type) was decreased by the miR-186 mimics, but remained unchanged in the YY1-3’UTR-MUT (mutant type) (Fig. 2F). These results indicated that miR-186 directly targets YY1.

3.3 MiR-186 mimics and knockdown of YY1 inhibited cell proliferation, but promoted cell apoptosis

To examine the roles played by miR-186 and its target gene YY1, YY1 expression was knocked down by siRNA, and the resultant effects on cell proliferation and apoptosis were examined (Fig. 3). We found that YY1 siRNA significantly downregulated the levels of YY1 mRNA (Fig. 3A) and protein expression (Fig. 3B), verifying that YY1 had been knocked down by YY1 siRNA. Next, cell proliferation was detected with the CCK-8 assay (Fig. 3C). Our results showed that the miR-186 mimics significantly inhibited A549 and HCC827 cell proliferation. Moreover, YY1 siRNA significantly inhibited the proliferation of both A549 and HCC827 cells. However, cell proliferation was more strongly inhibited by YY1 siRNA than by the miR-186 mimics.

Figure 3.

Silencing of YY1 by siRNA and its roles in cell proliferation and apoptosis. After transfection with YY1 siRNA, knockdown of YY1 was confirmed by qRT-PCR (A) and western blot (B). Next, the levels of cell proliferation in cultures of NC-, YY1 siRNA (si-YY1)-, and miR-186 mimics-transfected (C) A549 cells and (D) HCC827 cells were detected by the CCK-8 assay. Also, the rates of apoptosis among NC-, YY1 siRNA-, and miR-186 mimics-transfected A549 cells and HCC827 cells were detected by flow cytometry (D), and then calculated (E). ${}^{*}p<$ 0.05, ${}^{**}p<$ 0.01 vs. NC; # $p<$ 0.05 vs. si-YY1.

Figure 4.

Effects of miR-186 and YY1 on the migration and invasion capabilities of A549 cells and HCC827 cells. Transwell assays were performed to quantitate the migration and invasion capabilities of NC-, YY1 siRNA-, and miR-186 mimics-transfected (A) A549 cells and (B) HCC827 cells. ${}^{*}p<$ 0.05 vs. NC; # $p<$ 0.05 vs. miR-186 mimics.

The effects of miR-186 and YY1 siRNA on cell apoptosis were also evaluated (Fig. 3D and E). Both miR-186 and YY1 siRNA significantly increased the rates of apoptosis among A549 and HCC827 cells. However, the amount of apoptosis induction produced by YY1 siRNA was greater than that produced by miR-186 mimics.

When taken together, our results showed that miR-186 and YY1 siRNA inhibited cell proliferation, but promoted cell apoptosis. The degrees cell proliferation inhibition and apoptosis induction produced by YY1 siRNA were greater than those produced by miR-186. Our findings suggest that miR-186 inhibits cell proliferation, but promotes cell apoptosis by downregulating YY1.

3.4 MiR-186 mimics and knockdown of YY1 inhibited cell migration and invasion

Transwell assays were performed to examine whether miR-186 inhibited cell migration and invasion by downregulating YY1 (Fig. 4). In A549 cells (Fig. 4A), cell migration was inhibited by YY1 siRNA, and cell invasion was significantly inhibited by both miR-186 and YY1 siRNA. In HCC827 cells (Fig. 4B), cell migration and cell invasion were significantly inhibited by both miR-186 and YY1 siRNA. Furthermore, the degrees cell migration and invasion inhibition produced by YY1 siRNA were greater than those produced by miR-186 mimics. These findings suggest that miR-186 inhibits cell invasion and migration by downregulating YY1.

4. Discussion

In the present study, we found that miR-186 expression was suppressed in samples of NSCLC tissue, and negatively associated with YYI expression those tissues. Furthermore, our data showed that miR-186 inhibited cell proliferation, migration, and invasion, but induced apoptosis in NSCLC cells by directly targeting YY1, and may function as a tumor suppressor during NSCLC development. Thus, miR-186 and its target gene (YY1) could possibly serve as novel prognostic biomarkers and therapeutic targets for treatment of human NSCLC.

Recently, numerous oncogenes and tumor suppressors have demonstrated their involvement in regulating NSCLC development. In addition to putative protein-coding genes, non-coding miRNAs contain extremely well conserved RNA sequences of 21–24 nucleotides that play important roles in the development of different tumors by binding to the 3’-UTR of their target mRNAs. MiR-186 has been identified in various cancer tissues, and found to be either downregulated or upregulated in those tissues. Among the cancers in which miR-186 was downregulated were prostate cancer, colorectal neuroendocrine tumors, ovarian cancer, and NSCLC [15, 21, 22]. A single type of miRNA can target several different genes. Ectopic overexpression of miR-186 was shown to inhibit gastric cancer cell proliferation, invasion, and migration. In contrast, inhibition of miR-186 expression was shown to enhance cell proliferation, invasion, and migration by causing it to target twist1 [14]. Golgi phosphoprotein 3 (GOLPH3) is a target for miR-186. Overexpression of miR-186 was shown to arrest cells in their G0/G1 phase, and decrease their p21 and p27 levels by targeting GOLPH3 [15]. Another study found that miR-186 expression was significantly reduced in lung cancer tissues and A549 and HCC827 cells [17]. Knockdown of the miR-186 target gene MAP3K2 by RNAi inhibited lung cancer cell proliferation, migration, and invasion, and promoted cell apoptosis [17]. Consistent with those studies, we found that miR-186 levels were significantly reduced in lung cancer tissues, and also in A549 and HCC827 cells. We also identified YYI as new target gene for miR-186 and demonstrated that YY1 is involved in regulating cell proliferation, apoptosis, migration, and invasion. YY1 is also directly involved in regulating Snail1 gene transcription, and suppresses E-cadherin synthesis induced by the epithelial-mesenchymal transition process [23]. Snail is an important transcription factor induced by epithelial-mesenchymal transition [24], which is believed to ultimately promote tumor metastasis [25]. Knockdown of YY1 might inhibit cell migration and invasion through Snail in a downstream signaling pathway.

YY1 is a relatively conserved transcription factor that plays important roles in embryonic development, differentiation, cell proliferation, and metastasis [18], and helps regulate the invasion and metastasis of solid tumors [19]. Moreover, recent studies have shown that YY1 is involved in carcinogenesis, and can play either an oncogenic or suppressor role in tumor development and progression [26, 27].

Besides miR-186, YY1 is also the direct target of several other miRNAs, including miR-190 [28], miR-206 [29], miR-29 [30], miR-635 [31], and miR-34 [32]. MiR-635 transfection can significantly decrease endogenous YY1 expression, and thereby mimic the effects produced by inhibition of cell invasion caused by siRNA-mediated YY1 knockdown. This suggests that YY1 may be a direct target of miR-635 [31]. YY1 is also a target of miR-34, and contributes to gastric carcinogenesis [32]. A previous study using NUGC-3 cancer cells showed that overexpression of miR-34 family members suppressed carcinogenesis by downregulating YY1 expression. Alternatively, a study with SC-MI and AZ521 cancer cells showed that knockdown of miR-34 family members promoted tumorigenesis by up-regulating YY1 expression. In addition to miR-186, it is possible that other miRNAs can also regulate YY1, as the degrees of cell proliferation, migration, and invasion inhibition produced by YY1 siRNA, and also levels of cell apoptosis induced by YY1 siRNA, were greater than those produced by miR-186 mimics. Taken together, our results indicate that miR-186 inhibits the proliferation, migration, and invasion of non-small cell lung cancer cells by targeting Yin Yang 1.

Footnotes

Conflict of interest

The authors have no conflicts of interest to declare.

References

Zheng

Zeng

Zhang

Chen

and Chen

, National estimates of cancer prevalence in China, 2011, Cancer Lett 370 (2016), 33–38.

Torre

L.A.

Sauer

A.M.

Chen

M.S.

, Jr. Kagawa-Singer

Jemal

and Siegel

R.L.

, Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females, CA Cancer J Clin 66 (2016), 182–202.

Torre

L.A.

Bray

Siegel

R.L.

Ferlay

Lortet-Tieulent

and Jemal

, Global cancer statistics, 2012, CA Cancer J Clin 65 (2015), 87–108.

Siegel

Naishadham

and Jemal

, Cancer statistics, 2012, CA Cancer J Clin 62 (2012), 10–29.

Liu

and Kopani

, Rapidly progressive cataract formation associated with non-small-cell lung cancer therapy, J Cataract Refract Surg 42 (2016), 1838–1840.

Chew

Potter

and DiMattina

, Conjunctival metastasis as the presenting sign for stage IV lung cancer, Optom Vis Sci 91 (2014), e38–e42.

Herbst

R.S.

Heymach

J.V.

and Lippman

S.M.

, Lung cancer, N Engl J Med 359 (2008), 1367–1380.

Sause

Kolesar

Taylor

S.I.

Johnson

Livingston

Komaki

Emami

Curran

, Jr. Byhardt

Dar

A.R.

and Turrisi

, 3rd, Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group, Chest 117 (2000), 358–364.

Ahn

J.S.

Ahn

Y.C.

Kim

J.H.

Lee

C.G.

Cho

E.K.

Lee

K.C.

Chen

Kim

D.W.

Kim

H.K.

Min

Y.J.

Kang

J.H.

Choi

J.H.

Kim

S.W.

Zhu

Y.L.

Kim

S.R.

Lee

K.H.

Song

H.S.

Choi

Y.L.

Sun

J.M.

Jung

S.H.

Ahn

M.J.

and Park

, Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04, J Clin Oncol 33 (2015), 2660–2666.

10.

Curran

W.J.

, Jr. Paulus

Langer

C.J.

Komaki

Lee

J.S.

Hauser

Movsas

Wasserman

Rosenthal

S.A.

Gore

Machtay

Sause

and Cox

J.D.

, Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410, J Natl Cancer Inst 103 (2011), 1452–1460.

11.

Lewis

B.P.

Burge

C.B.

and Bartel

D.P.

, Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets, Cell 120 (2005), 15–20.

12.

Lai

E.C.

, Micro RNAs are complementary to 3’ UTR sequence motifs that mediate negative post-transcriptional regulation, Nat Genet 30 (2002), 363–364.

13.

Yao

Zhang

Chen

H.P.

Xie

Lan

Zhao

Z.W.

Zheng

X.L.

Wang

Z.B.

and Tang

C.K.

, MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine gamma-lyase in THP-1 macrophages, Atherosclerosis 250 (2016), 122–132.

14.

Cao

Sun

Zhang

and Song

, miR-186 affects the proliferation, invasion and migration of human gastric cancer by inhibition of Twist1, Oncotarget 7 (2016), 79956–79963.

15.

Hua

Xiao

Pan

Huang

Liao

Xian

and Yu

, miR-186 inhibits cell proliferation of prostate cancer by targeting GOLPH3, Am J Cancer Res 6 (2016), 1650–1660.

16.

Zhang

Sun

Fang

and Zhou

, miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC), Mol Biosyst 12 (2016), 3417–3424.

17.

Huang

She

Peng

Wang

Huang

Wang

and He

, MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer, Int J Oncol 49 (2016), 1437–1444.

18.

Wang

Devarajan

Reddy

S.P.

and Dai

J.L.

, Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression, Cancer Res 65 (2005), 10289–10297.

19.

Bonavida

and Baritaki

, The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-kappaB/Snail/YY1/RKIP/PTEN Circuitry, Crit Rev Oncog 16 (2011), 211–226.

20.

Chen

Zhou

Yuan

Peng

Zheng

and Li

, Expression of hsa-miR-186 and its role in human colon carcinoma cells, Nan Fang Yi Ke Da Xue Xue Bao 33 (2013), 654–660.

21.

Wang

Xia

Chu

Xia

Meng

Liu

and Liu

, Roles of miR-186 and PTTG1 in colorectal neuroendocrine tumors, Int J Clin Exp Med 8 (2015), 22149–22157.

22.

Sun

K.X.

Jiao

J.W.

Chen

Liu

B.L.

and Zhao

, MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1, J Ovarian Res 8 (2015), 80.

23.

Palmer

M.B.

Majumder

Cooper

J.C.

Yoon

Wade

P.A.

and Boss

J.M.

, Yin yang 1 regulates the expression of snail through a distal enhancer, Mol Cancer Res 7 (2009), 221–229.

24.

Zeng

Yao

Chen

Yan

Liu

Zhang

Feng

and Liu

, Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/syndecan-1/TGF-β autocrine loop, Oncotarget 7 (2016), 63324–63337.

25.

Zeng

Y.E.

Yao

X.H.

Yan

Z.P.

Liu

J.X.

and Liu

X.H.

, Potential signaling pathway involved in sphingosine-1-phosphate-induced epithelial-mesenchymal transition in cancer, Oncol Lett 12 (2016), 379–382.

26.

Atchison

Basu

Zaprazna

and Papasani

, Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects, Crit Rev Oncog 16 (2011), 143–161.

27.

Nicholson

Whitehouse

Naidoo

and Byers

R.J.

, Yin Yang 1 in human cancer, Crit Rev Oncog 16 (2011), 245–260.

28.

Beezhold

Liu

Kan

Meighan

Castranova

Shi

and Chen

, miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis, Toxicol Sci 123 (2011), 411–420.

29.

Song

and Wang

, Nuclear receptor SHP activates miR-206 expression via a cascade dual inhibitory mechanism, PLoS One 4 (2009), e6880.

30.

Wang

Garzon

Sun

Ladner

K.J.

Singh

Dahlman

Cheng

Hall

B.M.

Qualman

S.J.

Chandler

D.S.

Croce

C.M.

and Guttridge

D.C.

, NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma, Cancer Cell 14 (2008), 369–381.

31.

Zhang

Sun

Zhang

Liu

and Lin

, The microRNA-635 suppresses tumorigenesis in non-small cell lung cancer, Biomed Pharmacother 84 (2016), 1274–1281.

32.

Wang

A.M.

Huang

T.T.

Hsu

K.W.

Huang

K.H.

Fang

W.L.

Yang

M.H.

S.S.

Chi

C.W.

Lin

J.J.

and Yeh

T.S.

, Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis, Oncotarget 5 (2014), 5002–5016.

MiR-186 inhibits proliferation,migration,and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1

Abstract

BACKGROUND:

MATERIAL AND METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Background

2. Material and methods

2.1 Specimens

2.2 Cell culture

2.3 Transfection

Table 1 Primer sequences used for miRNA and mRNA expression analysis

2.5 qRT-PCR

2.6 Western blot studies

2.7 CCK-8 assay

2.9 Migration and invasion assay

2.10 Statistical analysis

3. Results

3.1 Expression of miR-186 and YY1 in NSCLC tissue

3.2 MiR-186 directly targeted YY1

4. Discussion

Footnotes

Conflict of interest

References

Table 1
Primer sequences used for miRNA and mRNA expression analysis